SEARCH

SEARCH BY CITATION

References

  • Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, et al (2010) Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363: 1991-2003
  • Andersen DH (1938) Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 56: 344-399
  • Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, et al (2012) Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67: 12-18
  • Hanrahan JW, Sampson HM, Thomas DY (2013) Novel pharmacological strategies to treat cystic fibrosis. Trends Pharmacol Sci 34: 119-125
  • Kreindler JL (2010) Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies. Pharmacol Ther 125: 219-229
  • Lukacs GL, Verkman AS (2012) CFTR: folding, misfolding and correcting the DeltaF508 conformational defect. Trends Mol Med 18: 81-91
  • Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073
  • Rowe SM, Verkman AS (2013) Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med 3, a009761
  • Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M, Cohen M, Armoni S, Yaakov Y, Pugatsch T, et al (2011) Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 38: 59-69
  • Odolczyk N, Fritsch J, Norez C, Servel N, Faria da Cunha M, Bitam S, Kupniewska A, Wiszniewski L, Colas J, Tarnowski K et al (2013) Discovery of novel ΔF508-CFTR correctors by targeting the specific conformation of a nucleotide binding domain. EMBO Mol Med 5: 1484-1501